Digital gamma camera developer Digirad of San Diego hasfiled forregulatory clearance with the Food and Drug Administration forits lead product, Notebook Imager. If and when the applicationis cleared, Notebook Imager will become the first solid-stategamma
Digital gamma camera developer Digirad of San Diego hasfiled forregulatory clearance with the Food and Drug Administration forits lead product, Notebook Imager. If and when the applicationis cleared, Notebook Imager will become the first solid-stategamma camera to be marketed commercially.
Notebook Imager is a portable gamma camera that uses a cadmiumzinc telluride detector array rather than scintillation crystalsand photomultiplier tubes, as conventional Anger-style camerasdo (SCAN 6/5/96). Digirad hopes to receive FDA clearance and beginmarketing the system next year.
To help ramp up its manufacturing and product-testing effort,Digirad completed a $6 million financing issued to a group ofventure-capital firms. Proceeds from the funding will be usedto finish beta-site testing and develop a manufacturing capacityfor Notebook Imager. The funding was led by Sorrento Ventures,and included Kingsbury Capital Partners and several individualinvestors.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.